CAS:254750-02-2 (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
NAME:(S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid CAS:254750-02-2 MF:C26H27F4N3O7 MW:569.51 PURITY:98%
Categories:
Material Chemistry
Email:sale06@alfachem.cn
Product introduction
| NAME | (S)-3-((S)-2-(2-(2-tert-butylphenylamino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid |
| CAS | 254750-02-2 |
| MF | C26H27F4N3O7 |
| MW | 569.51 |
| DENSITY | 1.386 |
| STORAGE | -20°C |
Description
Emricasan, also known as IDN-6556 and PF-03491390, is a potential drug that was invented in 1998 by Idun Pharmaceuticals . It was acquired by Pfizer in 2005 and then sold to Conatus Pharmaceuticals in 2010 . Emricasan is the first caspase inhibitor tested in humans and has received orphan drug status by the FDA . It is developed in such a way that it protects liver cells from excessive apoptosis . It has been in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis (scarring) and cirrhosis .
Key words:
Related Products
Related Products
Inquiry